Clinical Trials Browser

Terminated × Neoplasms × epacadostat × Clear all

NCT01685255 2019-03-11

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Phase 2 Terminated

Neoplasms, Ovarian Neoplasms